Latest / Decera Clinical Education Oncology Podcast
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:
Rechallenging patients with venetoclax and BTK inhibitors
Mechanism by which BTK inhibitors may reduce infusion reactions
Risk of secondary malignancies with BTK inhibition
Different cytogenetic findings and adverse event risk
Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon
Danielle M. Brander, MD…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.